3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
29
Neoplasms
5
Glioma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Glioblastoma
3
Rhabdoid Tumor
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Lymphoma
2
Liposarcoma
2
Fallopian Tube Neoplasms
2
Diffuse Intrinsic Pontine Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Sarcoma, Synovial
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Osteitis Deformans
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Interventions
Cyclophosphamide
32
Tacrolimus
29
fludarabine
27
Mycophenolic Acid
23
fludarabine phosphate
22
Busulfan
19
Whole-Body Irradiation
18
Melphalan
16
Methotrexate
15
Antilymphocyte Serum
14
Rituximab
12
Bortezomib
11
Stem Cell Transplantation
10
Cyclosporine
10
thymoglobulin
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Interviews as Topic
7
Filgrastim
7
Dexamethasone
7
Clofarabine
7
Blood Specimen Collection
6
Alemtuzumab
6
merphos
5
Voriconazole
5
Standard of Care
5
Nivolumab
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Neoplasms
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts